Eicosapentaenoic acid free fatty acid
Phase 3Small molecule
Eicosapentaenoic acid free fatty acid is one of 61 small molecule programs targeting Familial adenomatous polyposis. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Eicosapentaenoic acid free fatty acid
SS.L.A. Pharma AG
Phase 3
Eylea
RegeneronPreclinical
PORTRAZZA
Eli LillyPreclinical
Emend IV
Merck & Co.Preclinical
Ketalar
AAultman Health Foundation
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Vascepa
AAmarin Pharma Inc.
Preclinical
Andriol
AAuxilium
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SS.L.A. Pharma AG